Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

LENZ Therapeutics (LENZ) Income from Continuing Operations (2022 - 2025)

LENZ Therapeutics (LENZ) has disclosed Income from Continuing Operations for 4 consecutive years, with 35896000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations fell 183.72% to 35896000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 82116000.0 through Dec 2025, down 69.59% year-over-year, with the annual reading at 82127000.0 for FY2025, 65.02% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 35896000.0 at LENZ Therapeutics, down from 16700000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 10215000.0 in Q3 2024, with the low at 35896000.0 in Q4 2025.
  • Average Income from Continuing Operations over 4 years is 18818600.0, with a median of 15300000.0 recorded in 2024.
  • The sharpest move saw Income from Continuing Operations soared 51.4% in 2023, then plummeted 183.72% in 2025.
  • Over 4 years, Income from Continuing Operations stood at 26751000.0 in 2022, then increased by 29.8% to 18779000.0 in 2023, then skyrocketed by 32.63% to 12652000.0 in 2024, then tumbled by 183.72% to 35896000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 35896000.0, 16700000.0, and 14912000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.